PDF Print

Research Study


Research Study on Atopic Dermatitis / Eczema 

Title: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of an investigational medication in adult patients with moderate to severe atopic dermatitis (BREEZE-AD5) (IRB # STU 00206963)

Description: BREEZE-AD5 is a clinical research study conducted at Northwestern University by Dr. Jonathan Silverberg that will test if an investigational medication is better than placebo at treating moderate to severe atopic dermatitis. In this study, you will either get the study drug or a placebo.

Eligibility Criteria: Age 18 and above with a diagnosis of moderate to severe atopic dermatitis > 1 year, and have had inadequate response to treatment with topical medication or for whom topical treatment are medically inadvisable.

The study will take place at 676 N. St. Clair Street, Suite 1600, Chicago, IL 60611.

To contact a member of the research team, please either call (312) 503-5912 or email

[email protected]

CLICK HERE to view brochure 

Last Updated on Saturday, March 23, 2019 09:38 PM